Drugs / PEG-MetHuG-CSF
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06698861 | Aug 2024 → Feb 2025 | — | PharmaEssentia | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-MetHuG-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06698861 ↗ |
| Known as | P2203 | “A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy Volunteers” NCT06698861 ↗ |
| Route | Subcutaneous | “Single dose of PEG-MetHuG-CSF will be given SC injection at 2 mg in Cohort 1 and 6 mg in Cohort 2” NCT06698861 ↗ |